Basel Medical Group Ltd
BMGL
$2.02
-$0.17-7.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.14% | 1.25% | 5.29% | 5.82% | 3.75% |
| Total Other Revenue | 212.50% | 212.50% | -58.75% | -58.39% | 0.00% |
| Total Revenue | 0.23% | 1.33% | 4.71% | 5.23% | 3.76% |
| Cost of Revenue | 52.10% | 53.77% | 54.34% | 55.13% | -23.28% |
| Gross Profit | -53.64% | -53.13% | -35.68% | -35.35% | 63.63% |
| SG&A Expenses | 3,650.00% | 3,691.67% | -33.28% | -32.96% | -81.54% |
| Depreciation & Amortization | 34.08% | 35.61% | 10.56% | 11.07% | -15.19% |
| Other Operating Expenses | 255.26% | 259.15% | 2,195.95% | 2,186.67% | -31.24% |
| Total Operating Expenses | 76.61% | 78.56% | 37.10% | 37.79% | -23.90% |
| Operating Income | -130.77% | -131.11% | -79.88% | -79.79% | 175.32% |
| Income Before Tax | -116.54% | -116.72% | -69.90% | -69.75% | 232.96% |
| Income Tax Expenses | -99.96% | -99.96% | -178.20% | -178.54% | 11,430.00% |
| Earnings from Continuing Operations | -124.19% | -124.45% | -37.40% | -37.07% | 125.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.19% | -124.45% | -37.40% | -37.07% | 125.71% |
| EBIT | -130.77% | -131.11% | -79.88% | -79.79% | 175.32% |
| EBITDA | -129.43% | -129.74% | -79.05% | -78.92% | 171.80% |
| EPS Basic | -124.09% | -124.42% | -37.27% | -37.13% | 126.12% |
| Normalized Basic EPS | -116.67% | -116.67% | -70.00% | -69.68% | 232.53% |
| EPS Diluted | -124.09% | -124.42% | -37.27% | -37.13% | 126.12% |
| Normalized Diluted EPS | -116.67% | -116.67% | -70.00% | -69.68% | 232.53% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |